Skip to main content
Swing Capital

Orchid Pharma Ltd

NSE: ORCHPHARMA BSE: 524372Pharma

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

₹712
52W: ₹471 — ₹899
PE 72.8 · Book ₹265 · +169% vs book
Market Cap₹3,611 Cr
Stock P/E72.8Price to Earnings
ROCE8.54%Return on Capital
ROE8.4%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Company has delivered good profit growth of 22.1% CAGR over last 5 years

Weaknesses

  • −Stock is trading at 2.69 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Tax rate seems low
  • −Company has a low return on equity of 7.32% over last 3 years.
  • −Earnings include an other income of Rs.41.1 Cr.
  • −Promoter holding has decreased over last 3 years: -20.1%

Shareholding Pattern

Promoters69.84%
FIIs0.87%
DIIs20.24%
Public9.04%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters69.84%69.84%69.84%69.84%69.84%69.84%69.84%69.84%
FIIs1.42%1.94%▲0.52.53%▲0.62.69%▲0.21.39%▼1.31.56%▲0.21.17%▼0.40.87%▼0.3
DIIs18.93%18.3%▼0.619%▲0.720.1%▲1.119.43%▼0.719.04%▼0.419.38%▲0.320.24%▲0.9
Public9.82%9.94%▲0.18.63%▼1.37.37%▼1.39.34%▲2.09.57%▲0.29.61%▲0.09.04%▼0.6

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales198.76220.59217.1244.41222.7217.34237.48172.93193.52207.27
Expenses175.06184.68188.17211.16193.11190.98203.15158.75194.2204.44
Operating Profit23.735.9128.9333.2529.5926.3634.3314.18-0.682.83
OPM %11.92%16.28%13.33%13.6%13.29%12.13%14.46%8.2%-0.35%1.37%
Net Profit20.2430.5533.1929.125.6323.9127.8518.22.23-5.82
EPS ₹3.996.026.545.745.054.715.493.590.44-1.15

AI Insights

Revenue Trend

TTM revenue at ₹811Cr, down 12% YoY. OPM at 6%.

Debt Position

Borrowings at ₹197Cr. Debt-to-equity ratio: 0.15x. Healthy balance sheet.

Capex Cycle

CWIP at ₹54Cr (9% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 20.24% (+6.76pp change). FIIs: 0.87% (-7.71pp change). Promoters hold 69.84%.

Margin & Efficiency

ROCE improving from -2% (Sep 2013) to 9% (Mar 2025). Working capital days: 152.

Valuation

PE 72.8x with 8.54% ROCE. Price is 169% above book value of ₹265. Dividend yield: 0%.

Recent Announcements